Comments on: Not what Merck wants to hear . . . http://www.kevinmd.com/blog/2004/08/not-what-merck-wants-to-hear.html medical blog Sun, 22 Nov 2009 22:50:49 -0500 http://wordpress.org/?v=2.8.4 hourly 1 By: GB http://www.kevinmd.com/blog/2004/08/not-what-merck-wants-to-hear.html/comment-page-1#comment-51653 GB Tue, 07 Sep 2004 13:50:00 +0000 http://clients.emmense.com/kevinmd/2004/08/not-what-merck-wants-to-hear.html#comment-51653 I have been taking 25mg Vioxx since the product was approved.<br />I have also had Atrial Fib about once per week, usually starting at 3 Am and ususally ending about the time I hit exit 5 on the way to St. Joes Hospital, Nashua.<br />3 or 4 times it did not "break" until recorded.<br />I stopped using vioxx when I learned of this troubling issue and haven't had a bout since. About 3 weeks. I have been taking 25mg Vioxx since the product was approved.
I have also had Atrial Fib about once per week, usually starting at 3 Am and ususally ending about the time I hit exit 5 on the way to St. Joes Hospital, Nashua.
3 or 4 times it did not “break” until recorded.
I stopped using vioxx when I learned of this troubling issue and haven’t had a bout since. About 3 weeks.

]]> By: vesalius http://www.kevinmd.com/blog/2004/08/not-what-merck-wants-to-hear.html/comment-page-1#comment-51642 vesalius Fri, 27 Aug 2004 10:40:00 +0000 http://clients.emmense.com/kevinmd/2004/08/not-what-merck-wants-to-hear.html#comment-51642 Hi Kevin, in case you haven't had any info yet:<br /><br />1. I can't find the abstract that was presented at the meeting (which was this one: http://www.pharmacoepi.org/meetings/20thconf/index.cfm )<br /><br />The only thing available on the site is the title:<br />59. Risk of Acute Cardiac Events among<br />Patients Treated with Cyclooxygenase-2<br />Selective and Non-Selective Nonsteroidal<br />Antiinflammatory Drugs [571]<br />David J Graham, David Campen, Craig<br />Cheetham, Rita Hui, Michele Spence,<br />Wayne A Ray. (United States)<br /><br />2. This group already has a publication out from June this year on the use of the 50mg rofecoxib. See PMID 15170762 if interested. (it does not seem to involve looking at MI, just at the frequency of high dose rofecoxib prescription).<br /><br />3. A Harvard group published a case-control study of 54,475 patients in Circulation in May, lloking at coxibs and AMI. They found "current rofecoxib use was associated with an elevated relative risk of AMI compared with celecoxib use and no NSAID use. Dosages of rofecoxib >25 mg were associated with a higher risk than dosages < or =25 mg. The risk was elevated in the first 90 days of use but not thereafter."<br /><br />See PMID 15096449 for the money.<br /><br />best, Hi Kevin, in case you haven’t had any info yet:

1. I can’t find the abstract that was presented at the meeting (which was this one: http://www.pharmacoepi.org/meetings/20thconf/index.cfm )

The only thing available on the site is the title:
59. Risk of Acute Cardiac Events among
Patients Treated with Cyclooxygenase-2
Selective and Non-Selective Nonsteroidal
Antiinflammatory Drugs [571]
David J Graham, David Campen, Craig
Cheetham, Rita Hui, Michele Spence,
Wayne A Ray. (United States)

2. This group already has a publication out from June this year on the use of the 50mg rofecoxib. See PMID 15170762 if interested. (it does not seem to involve looking at MI, just at the frequency of high dose rofecoxib prescription).

3. A Harvard group published a case-control study of 54,475 patients in Circulation in May, lloking at coxibs and AMI. They found “current rofecoxib use was associated with an elevated relative risk of AMI compared with celecoxib use and no NSAID use. Dosages of rofecoxib >25 mg were associated with a higher risk than dosages < or =25 mg. The risk was elevated in the first 90 days of use but not thereafter."

See PMID 15096449 for the money.

best,

]]>